Table 3.

Multivariate analysis for OS, LFFS, DMFS

Variables	HR (95 % CI)	P value
OS
Age (>51 vs. ≦51)	0.77 (0.440–1.342)	0.354
Gender (male vs. female)	4.11 (0.942–17.92)	0.060
ECE (negative vs. positive)	0.55 (0.257–1.163)	0.117
Margin (negative vs. positive)	0.52 (0.295–0.916)	0.024
LNR (≧0.1 vs. < 0.1)	2.92 (1.367–6.242)	0.006
Absolute number of lymph nodes metastases (1 vs. ≧2)	1.02 (0.661–1.575)	0.928
Stage (III + IV vs I + II)	1.99 (0.744–5.319)	0.170
Primary (other primary site vs. oral cavity)	0.59 (0.303–1.160)	0.127
LFFS
Age (>51 vs. ≦51)	0.34 (0.156–0.729)	0.006
Gender (male vs. female)	6.10 (0.806–46.14)	0.080
ECE (negative vs. positive)	0.39 (0.145–1.040)	0.060
Margin (negative vs. positive)	0.81 (0.358–1.837)	0.615
LNR (≧0.1 vs. < 0.1)	4.12 (1.604–10.59)	0.003
Absolute number of lymph nodes metastases (1 vs. ≧2)	1.15 (0.674–1.967)	0.606
Stage (III + IV vs I + II)	2.09 (0.576–7.567)	0.263
Primary (other primary site vs. oral cavity)	0.33 (0.112–0.957)	0.041
DMFS
Age (>51 vs. ≦51)	0.34 (0.132–0.865)	0.024
Gender (male vs. female)	2.80 (0.360–22.14)	0.323
ECE (negative vs. positive)	0.68 (0.225–2.057)	0.495
Margin (negative vs. positive)	2.37 (0.682–8.256)	0.175
LNR (≧0.1 vs. < 0.1)	3.10 (0.957–10.09)	0.059
Absolute number of lymph nodes metastases (1 vs. ≧2)	0.85 (0.444–1.635)	0.630
Stage (III + IV vs I + II)	6.90 (0.176–41.03)	0.199
Primary (other primary site vs. oral cavity)	0.74 (0.238–2.270)	0.592

OS overall survival, LFFS local failure free survival, DMFS distant metastasis-free survival